19 results
The objective of the current proposal is to assess, in a phase 1/2 study, the safety and efficacy of this synthetic vaccine SLP-HPV-01® in HIV+ men with CD4 counts > 350 x 10E6/l and intra-anal high-grade, HPV16 positive AIN, who failed on…
To assess the effect of switching CML patients, who have been treated with imatinib *2 years and who have stable detectable molecular residual disease above 0.01% (IS), to the combination of Nilotinib and PegIFN, in terms of the proportion of…
To investigate sustained HBeAg response to peg-interferon alfa-2b in chronic HBeAg-positive hepatitis Bpatients who are pretreated with nucleos(t)ide analogues, thereby lowering viral load
To determine the influence of OATP1B inhibition, through rifampicin exposure, on the metabolism and plasma pharmacokinetics of sorafenib and its metabolites.
Primary objectives of the study are to assess whether the administration of p53-SLP together with the local administration of IFNα is safe and able to induce a strong (directly ex-vivo detectable) p53-specific CD4+ T-cell response. Secondary…
Primary : To assess the effect of multiple doses of rifampicin on the single-dose pharmacokinetics (PK) of tasquinimodSecondary : To assess the safety and tolerability of multiple doses of rifampicin with a single dose of tasquinimod
To investigate sustained HBeAg response to peg-interferon alfa-2b in chronic HBeAg-positive hepatitis B patients who are pretreated with nucleos(t)ide analogues, thereby lowering viral loadDetermine the effect of PEG-IFNa on NK cell function and…
To primary objective is to demonstrate a reduction in lipoteichoic acid release in patients with pneumococcal pneumonia treated with rifampicin. This will be done by measuring lipoteichoic acid in serum and urine.Evaluable patients for Intention-to-…
Primary objective:- To evaluate dose modifications of the new Kaletra Meltrex tablets (lopi-navir/ritonavir 200/50 mg) when combined with rifampicin in healthy volunteersSecondary objectives:- To evaluate the safety of combined use of the new…
Main objective: response rate and tumour size reduction by neoadjuvant chemotherapy.
The primary objective is to determine the efficacy of neo-adjuvant chemotherapy to reduce tumour size below 2 cm in diameter and thus enabling conisation.
Primary objectives: • To assess the safety and tolerability of different doses of the ISA101 vaccine with or without pegylated IFNα as combination therapy with carboplatin and paclitaxel.• To qualitatively assess the safety profile of ISA101b…
The study will be performed in 2 cohorts, Cohort 1 and Cohort 2. In Cohort 1, it will be investigated what the effect is of itraconazole on how quickly and to what extent APX001 is absorbed and excreted by the body (this is called pharmacokinetics…
To determine the effectiveness of the currently recommended treatment regimens.
The purpose of the study is to determine how a single administration of rifampicin influences the uptake and breakdown of ACT-246475. Furthermore, the safety and tolerability of ACT-246475 when administered after administration of rifampicin, will…
Main objective: response rate and tumour size reduction by chemotherapy
To assess the feasibility of preserving fertility in women with 2018 FIGO stage IB2 cervical cancer with lesions measuring >2 cm - <=4 cm.
The primary objective of this study is to determine the immune-activating capacity of treatment with pembrolizumab and carboplatin/paclitaxel in the neo-adjuvant setting of primary stage IV ovarian cancer as measured by the alteration in magnitude…
To investigate whether (neo)adjuvant systemic treatment of intensified alkylating chemotherapy with peripheral stem cell rescue (mini-CTC) compared to AC-CP chemotherapy followed by 1-year olaparib monotherapy substantially improves overall survival…